Although progressively increasing FGF23 concentrations in CKD help to mitigate hyperphosphatemia, elevated FGF23 levels have been independently associated with a multitude of adverse “off-target” effects, including faster CKD progression17–19. This evidence concerns the gene FGF23 and hyperphosphatemia.